Zydus Cadila has launched mesalamine delayed release tablets, used for the treatment of ulcerative colitis, in the US market.
"Zydus Cadila has commercially launched its mesalamine delayed release tablets in the US market. Zydus was the first to file an Abbreviated New Drug Application (ANDA) for the generic version of Lialda," the company said in a BSE filing today.
Zydus Cadila said this product is the only generic of Lialda available to patients in the US.
The Gujarat-based group has more than 130 USFDA approvals and has filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Shares of Cadila Healthcare, the group's listed entity, were trading at Rs 537.40 per scrip on BSE, up 2.37 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
